Work

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.3076

Authors: R. Tibes, G. S. Falchook, D. D. Von Hoff, G. J. Weiss, T. Iyengar, R. Kurzrock, L. Pestano, A. M. Lowe, R. S. Herbst

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589190489

Cites:

Cited by: 46

Related to: 10